These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 6957239)

  • 21. Pharmacology, clinical efficacy and adverse effects of vindesine sulfate, a new vinca alkaloid.
    Cersosimo RJ; Bromer R; Licciardello JT; Hong WK
    Pharmacotherapy; 1983; 3(5):259-74. PubMed ID: 6359081
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative pharmacokinetics of vindesine, vincristine and vinblastine in patients with cancer.
    Nelson RL; Dyke RW; Root MA
    Cancer Treat Rev; 1980 Sep; 7 Suppl 1():17-24. PubMed ID: 7438117
    [No Abstract]   [Full Text] [Related]  

  • 23. Cross-resistance of cultured murine leukemia vincristine-resistant P388 cells to vinblastine, vindesine, and bis (N-ethylidene vindesine) disulfide, disulfate.
    Wilkoff LJ; Dulmadge EA
    J Natl Cancer Inst; 1982 Jun; 68(6):1023-6. PubMed ID: 6953266
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Collateral sensitivity of a methotrexate-resistant L1210 cell line to the vinca alkaloids.
    Poppitt DG; McGown AT; Fox BW
    Cancer Chemother Pharmacol; 1984; 13(1):43-6. PubMed ID: 6733841
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Influence of vindesine on the lytic phase of mouse natural cytotoxicity against human leukemic cells.
    Pastore S; De Vecchis L; Migliorati G; Frati L; Bonmassar AG
    J Immunopharmacol; 1982-1983; 4(3):183-97. PubMed ID: 6223955
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase II clinical trial with vindesine for remission induction in acute leukemia, blastic crisis of chronic myeloid leukemia, lymphosarcoma, and hodgkin's disease: absence of cross-resistance with vincristine.
    Mathé G; Misset JL; De Vassal F; Gouveia J; Hayat M; Machover D; Belpomme D; Pico JL; Schwarzenberg L; Ribaud P; Musset M; Jasmin C; De Luca L
    Cancer Treat Rep; 1978 May; 62(5):805-9. PubMed ID: 274996
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vindesine-prednisone in the treatment of blast crisis of chronic myeloid leukemia.
    Lemoine F; Najman A; Laporte JP; Gorin NC; Duhamel G
    Cancer Treat Rep; 1985 Feb; 69(2):203-4. PubMed ID: 3855698
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The action of two Vinca alkaloids on B16 melanoma in vitro.
    Donoso JA; Himes RH
    Cancer Biochem Biophys; 1984 Jun; 7(2):133-45. PubMed ID: 6467174
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of chronic myelogenous leukemia in blastic crisis with chemotherapy incorporating vindesine-prednisolone.
    Uzuka Y; Saito Y
    Cancer Treat Rep; 1985 Nov; 69(11):1297-9. PubMed ID: 3867403
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differential cellular retention of vincristine and vinblastine by cultured human promyelocytic leukemia HL-60/Cl cells: the basis of differential toxicity.
    Ferguson PJ; Cass CE
    Cancer Res; 1985 Nov; 45(11 Pt 1):5480-8. PubMed ID: 3863705
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Administration of vindesine sulfate for the treatment of malignant hematological tumors].
    Ueda T; Masaoka T; Shibata H; Kubota Y; Saigo K; Kusakabe H; Takubo T; Nakamura H; Yoshitake J; Ishigami S
    Gan To Kagaku Ryoho; 1982 Feb; 9(2):306-15. PubMed ID: 6764103
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Two cases of acute myelogenous leukemia with eosinophilia which progressed into complete remission with the treatment mainly consisting of vindesine and prednisolone].
    Yamada O; Naohara T; Aoyama M; Totsuka K; Muto K; Ito N; Otani T; Oshimi K; Mizoguchi H; Okada M
    Rinsho Ketsueki; 1983 Jan; 24(1):45-50. PubMed ID: 6573521
    [No Abstract]   [Full Text] [Related]  

  • 33. Pharmacokinetics of vincristine, vinblastine, and vindesine in rhesus monkeys.
    Sethi VS; Surratt P; Spurr CL
    Cancer Chemother Pharmacol; 1984; 12(1):31-5. PubMed ID: 6690071
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The comparative clinical pharmacology and pharmacokinetics of vindesine, vincristine, and vinblastine in human patients with cancer.
    Nelson RL
    Med Pediatr Oncol; 1982; 10(2):115-27. PubMed ID: 7070351
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of chronic myeloid leukemia blast crisis with vindesine and prednisone.
    Jehn U; Mezger J
    Cancer Treat Rep; 1985 Apr; 69(4):445-8. PubMed ID: 3857971
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Correlation of the clinical neurotoxicity of the vinca alkaloids vincristine, vinblastine, and vindesine with their effects on cultured rat midbrain cells.
    King KL; Boder GB
    Cancer Chemother Pharmacol; 1979; 2(4):239-42. PubMed ID: 455582
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Vindesine, a new cytostatic agent from the vinca alkaloids].
    Goldhirsch A; Joss R; Sonntag RW; Brunner KW
    Dtsch Med Wochenschr; 1980 Jun; 105(26):931-5. PubMed ID: 6931709
    [No Abstract]   [Full Text] [Related]  

  • 38. Increased schedule-dependent synergism of vindesine versus vincristine in combination with methotrexate against L1210 leukemia.
    Chello PL; Sirotnak FM
    Cancer Treat Rep; 1981; 65(11-12):1049-53. PubMed ID: 7296551
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of acute lymphoblastic leukemia in adults with combination chemotherapy incorporating vindesine and prednisolone.
    Saito Y; Uzuka Y
    Tohoku J Exp Med; 1983 Apr; 139(4):421-2. PubMed ID: 6575488
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical pharmacokinetics of vindesine: repeated treatments by intravenous bolus injections.
    Rahmani R; Martin M; Favre R; Cano JP; Barbet J
    Eur J Cancer Clin Oncol; 1984 Nov; 20(11):1409-17. PubMed ID: 6542010
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.